ALTERNATIVES FOR ANIMAL STUDIES: BPRC PARTICIPATES IN EUROPEAN PROJECT
1 February 2016
BPRC is involved in a new European research project on replacement of animal studies for vaccine batch testing.
BPRC takes part in the recently started IMI2 project “Vaccine lot to vaccine lot comparison by consistency testing (VAC2VAC)”, part of the Horizon 2020 initiative, anticipated to start on March 1, 2016. The project aims to develop alternatives for animal experiments that are conducted for batch release of ‘old vaccines’, such as tetanus and diphtheria toxoid vaccines. The animal tests are part of either safety or potency assays and are mandatory for release of a new vaccine batch/lot.
The principle idea behind the project is that, as a high number of lots/batches has been produced over the years, it should be possible to replace these animal tests by alternative safety and potency assays that relate to previously produced, safe and potent batches/lots of the vaccine.
The project was initiated by the Dutch Institute for Translational Vaccinology (Intravacc) that originates from the National Institute of Public Health (RIVM). The pharmaceutical industry and the regularory authorities of the EC and of many European countries are part of the project consortium. BPRC has a role in the in-depth physical analysis of the vaccines, synthesis of vaccine specific reagentia without use of animals and the in-vitro analysis of the potency of the vaccines using reporter cell-lines.VAC2VAC Press Release (0,4MB)